{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:18:46Z","timestamp":1788826726834,"version":"build-2803163510"},"reference-count":8,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:p>This research letter reports on a case series of 10 patients with bullous pemphigoid treated with rituximab combined with omalizumab.<\/jats:p>","DOI":"10.1001\/jamadermatol.2023.4508","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T16:34:20Z","timestamp":1700670860000},"page":"107","source":"Crossref","is-referenced-by-count":11,"title":["Rituximab and Omalizumab Combination Therapy for Bullous Pemphigoid"],"prefix":"10.1001","volume":"160","author":[{"given":"Stephanie T.","family":"Le","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of California, Davis, Sacramento."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Herbert","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Davis, Sacramento."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene\u00e9","family":"Haughton","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Davis, Sacramento."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Nava","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Davis, Sacramento."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atrin","family":"Toussi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Davis, Sacramento."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ji-Xu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Davis, Sacramento."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanual","family":"Maverakis","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Davis, Sacramento."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"dld230023r1","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/rheumatology\/kev438","article-title":"Predictors of disease relapse in IgG4-related disease following rituximab.","volume":"55","author":"Wallace","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"dld230023r2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928621","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review.","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"dld230023r3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"dld230023r4","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/bjd.v184.6","article-title":"International validation of the Bullous Pemphigoid Disease Area index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid.","volume":"184","author":"Masmoudi","year":"2021","journal-title":"Br J Dermatol"},{"issue":"24","key":"dld230023r5","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris.","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"key":"dld230023r6","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.3389\/fimmu.2019.02331","article-title":"The intersection of IgE autoantibodies and eosinophilia in the pathogenesis of bullous pemphigoid.","volume":"10","author":"Messingham","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"dld230023r7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"dld230023r8","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/jde.v50.5","article-title":"Clinical effect of omalizumab as an adjuvant treatment to rituximab in patient with refractory bullous pemphigoid.","volume":"50","author":"Kwon","year":"2023","journal-title":"J Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2812284\/jamadermatology_le_2023_ld_230023_1705092752.14265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T17:51:26Z","timestamp":1705513886000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2812284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.4508","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}